{"generic":"Fomivirsen Sodium","drugs":["Fomivirsen Sodium","Vitravene"],"mono":{"0":{"id":"924824-s-0","title":"Generic Names","mono":"Fomivirsen Sodium"},"1":{"id":"924824-s-1","title":"Dosing and Indications","sub":{"0":{"id":"924824-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>AIDS - Cytomegaloviral retinitis, Second-line treatment:<\/b> induction, 330 mcg (0.05 mL) INTRAVITREALLY every other week for 2 doses<\/li><li><b>AIDS - Cytomegaloviral retinitis, Second-line treatment:<\/b> maintenance, 330 mcg (0.05 mL) INTRAVITREALLY every 4 weeks<\/li><\/ul>"},"1":{"id":"924824-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy in children have not been established"},"3":{"id":"924824-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>AIDS - Cytomegaloviral retinitis, Second-line treatment<br\/>"}}},"3":{"id":"924824-s-3","title":"Contraindications\/Warnings","sub":{"0":{"id":"924824-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to fomivirsen products<\/li><li>IV or intravitreal cidofovir therapy within 2-4 weeks; risk for exaggerated ocular inflammation<\/li><\/ul>"},"2":{"id":"924824-s-3-11","title":"Pregnancy Category","mono":"Fomivirsen: C (FDA)<br\/>"},"3":{"id":"924824-s-3-12","title":"Breast Feeding","mono":"Fomivirsen: Micromedex: Infant risk cannot be ruled out.<br\/>"}}},"5":{"id":"924824-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Blurred vision, Inflammatory disorder of the eye, Iritis, vitreitis (1 in 4 patients), Pain in eye<br\/><b>Serious<\/b><br\/><b>Ophthalmic:<\/b>Raised intraocular pressure, Generally transient<br\/>"},"6":{"id":"924824-s-6","title":"Drug Name Info","sub":{"0":{"id":"924824-s-6-17","title":"US Trade Names","mono":"Vitravene<br\/>"},"2":{"id":"924824-s-6-19","title":"Class","mono":"<ul><li>Antisense Phosphorothioate Oligonucleotide<\/li><li>Antiviral<\/li><\/ul>"},"3":{"id":"924824-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"924824-s-9","title":"Administration","mono":"<b>Intravitreal<\/b><br\/>for intravitreal injection only <br\/>"},"10":{"id":"924824-s-10","title":"Monitoring","mono":"<ul><li>light perception, optic nerve head perfusion post-injection; if not completely perfused in 7-10 minutes, perform anterior chamber paracentesis<\/li><li>improvement in retinitis<\/li><li>intraocular pressure at each visit<\/li><\/ul>"},"13":{"id":"924824-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause decreased visual acuity. Patient should avoid driving or other activities requiring clear vision until drug effects are realized.<\/li><li>This drug may cause blurred vision, uveitis, iritis, vitritis, or eye pain.<\/li><\/ul>"}}}